End-Stage Kidney Disease (ESKD) and Heart Failure (HF) usually coexist; one condition lowers the prognosis of the other. Nearly 50% of dialysis patients' fatalities are caused by HF. There is a dearth of information addressing the management of HF in patients on dialysis, and the majority of the current evidence is observational, despite the fact that patients with ESKD comprise an exceedingly high-risk cohort. Similar to this, in clinical practice, guideline-directed medicinal therapy for HF is frequently reduced in dose or stopped in patients with ESKD who are receiving dialysis due to worries about tolerability and safety.
